Metabolic · In Clinical Trials
Pemvidutide
No lawful US pathway
01 · Overview
Pemvidutide (ALT-801) is a dual receptor agonist targeting the glucagon-like peptide-1 (GLP-1) and glucagon receptors, given once weekly by subcutaneous injection (PMID 39002641). It is designed to combine the appetite-suppressing and insulin-related effects of GLP-1 with glucagon receptor activity that acts directly on the liver to stimulate fatty acid oxidation and inhibit fat synthesis (PMID 39002641).
It is being developed mainly for metabolic dysfunction-associated steatohepatitis (MASH) and obesity.
02 · Research summary & key findings
In a 12-week randomized trial in adults with MASLD, pemvidutide reduced liver fat content by 46.6 to 68.5 percent versus 4.4 percent with placebo, with up to 4.3 percent weight loss and no serious adverse events (PMID 39002641). In the 24-week IMPACT phase 2b trial in biopsy-confirmed MASH with F2 to F3 fibrosis, 52 to 58 percent of pemvidutide patients achieved MASH resolution versus 20 percent on placebo, but fibrosis improvement was not significantly different from placebo (PMID 41237796). Obesity results from its phase 2 program have not yet appeared as a peer-reviewed abstract in PubMed.
03 · Regulatory status
Pemvidutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Pemvidutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Pemvidutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study J Hepatol, 2025. PMID 39002641
- [2]Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study Lancet, 2025. PMID 41237796
Primary literature
- PubMed: "Pemvidutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Pemvidutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Pemvidutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.